Ficerafusp alfa Clinical Trials
2 recruitingDrug
Phase 22Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 2
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute32 enrolled2 locationsNCT07465276
Recruiting
Phase 2Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics650 enrolled129 locationsNCT06788990